Breakthrough Study of Stapokibart in Seasonal Allergic Rhinitis
Keymed Biosciences Inc. (HKEX: 02162) has released significant results from the Phase III trial of its novel IL-4R? antibody known as stapokibart, aimed at providing relief for individuals suffering from moderate-to-severe seasonal allergic rhinitis (SAR). This landmark study, led by Professor Luo Zhang, highlights the first clinical findings on an IL-4R?-targeted biologic for SAR, reflecting a pivotal advancement in the field of allergic rhinitis treatment.
Effective Relief from Symptoms
The Phase III study clearly demonstrates that stapokibart effectively alleviates clinical symptoms associated with SAR, significantly improving the quality of life for patients who have not found sufficient relief from standard therapy options. This innovative treatment represents a pivotal shift in managing allergic rhinitis, offering hope to the millions affected by this condition worldwide.
Rapid and Effective Nasal Symptom Control
The results indicate that patients treated with stapokibart experienced a rapid alleviation of nasal obstruction symptoms. Notably, by Day 2, those in the treatment group showed significantly greater relief compared to the placebo group. By Day 7, an impressive 72% of patients reported clear nasal breathing, with cumulative rates reaching 86% by Week 2 and 94% by Week 4.
Potency and Continuity of Effect
Stapokibart users noted a significant reduction in the daily reflective total nasal symptom score (rTNSS) as early as Day 4, where scores improved by 2.7 points from baseline, which surpassed the improvements of the placebo group. During the 2-week treatment phase, a remarkable 3.6-point improvement was achieved compared to baseline, and the 4-week analysis indicated a 4.9-point reduction in rTNSS, showcasing substantial progress in patient outcomes.
Marked Improvements in Ocular Symptoms
The study also monitored ocular symptom improvements, demonstrating that stapokibart provided clinically significant reductions in daily reflective Total Ocular Symptom Score (rTOSS). Noteworthy enhancements of 2.6 points at Week 2 and 3.7 points at Week 4 outperformed placebo results, with a majority of patients achieving mild or no ocular symptoms by the conclusion of the study.
Reducing Inflammation at Its Source
Another critical finding of the study was the reduction in type 2 inflammatory biomarkers among those treated with stapokibart, highlighting its dual action against allergic rhinitis. Within the 4-week timeframe, notable declines in total serum IgE and allergen-specific IgE levels were observed, along with reductions in nasal secretion biomarkers like cystatin SN and eotaxin-3.
Safety Profile of Stapokibart
In terms of safety, stapokibart exhibited a favorable profile among study participants, with rates of treatment-emergent adverse events comparable to those experienced by participants receiving placebo. No serious adverse events were reported, contributing to the positive evaluation of stapokibart as a viable treatment option for SAR.
Pioneering Future Research
Conclusively, the PHECDA trial marks a significant leap forward in targeted biologic therapy for seasonal allergic rhinitis. Following these findings, stapokibart received approval from China's National Medical Products Administration (NMPA), establishing it as the world's first IL-4R? monoclonal antibody for SAR. This approval not only presents a new treatment alternative for patients enduring moderate-to-severe refractory SAR but also reinforces the leadership position of clinical scientists in the field of allergic rhinitis research.
Frequently Asked Questions
What is stapokibart?
Stapokibart is an IL-4R? targeted antibody developed by Keymed Biosciences for treating moderate-to-severe seasonal allergic rhinitis.
What were the main findings of the Phase III study?
The Phase III study found that stapokibart significantly improved nasal and ocular symptoms and reduced inflammatory biomarkers in patients with SAR.
How quickly did patients experience relief?
Patients using stapokibart reported significant improvements in nasal obstruction by Day 2, with most achieving optimal results by Week 4.
Was stapokibart safe for patients?
Yes, the study indicated that stapokibart had a favorable safety profile, with adverse events comparable to the placebo group.
When was stapokibart approved?
Stapokibart received approval from China’s National Medical Products Administration (NMPA) as an innovative treatment for SAR.
